Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

Wed, 22nd May 2024 09:53

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

----------

FTSE 100

----------

Morgan Stanley raises BT Group price target to 215 (200) pence - 'overweight'

----------

Berenberg reinitiates Weir Group with 'buy' - price target 2,600 pence

----------

Barclays raises M&G price target to 215 (205) pence - 'underweight'

----------

Barclays raises Aviva price target to 500 (480) pence - 'equal weight'

----------

Goldman Sachs raises Kingfisher price target to 260 (250) pence - 'neutral'

----------

Stifel cuts Burberry price target to 1,150 (1,300) pence - 'hold'

----------

Stifel raises AstraZeneca price target to 13,700 (12,800) pence - 'buy'

----------

Deutsche Bank cuts BAT price target to 3,450 (4,000) pence - 'buy'

----------

Deutsche Bank raises Imperial Brands target to 2,600 (2,325) pence - 'buy'

----------

Jefferies cuts Prudential price target to 1,350 (1,750) pence - 'buy'

----------

Goldman Sachs raises IMI price target to 2,150 (2,020) pence - 'buy'

----------

FTSE 250

----------

Berenberg cuts Grainger price target to 299 (305) pence - 'buy'

----------

Barclays raises Renewables Infrastructure Group target to 124 (122) pence - 'overweight'

----------

Barclays cuts SDCL Energy Efficiency target to 79 (80) pence - 'equal weight'

----------

Barclays cuts Octopus Renewables Infrastructure target to 88 (98) pence - 'overweight'

----------

Barclays raises Greencoat UK Wind target to 167 (166) pence - 'overweight'

----------

Barclays raises Foresight Solar Fund target to 102 (99) pence - 'equal-weight'

----------

Barclays cuts Bluefield Solar Income Fund target to 128 (132) pence - 'overweight'

----------

Barclays cuts NextEnergy Solar Fund to 'equal weight' (overweight) - price target 87 (100) pence

----------

Barclays raises JLEN Environmental Assets to 'overweight' (equal-weight) - price target 110 pence

----------

RBC cuts HICL Infrastructure price target to 165 (175) pence - 'outperform'

----------

Jefferies cuts Assura to 'hold' (buy) - price target 45 (52) pence

----------

Deutsche Bank raises Currys price target to 80 (58) pence - 'hold'

----------

Deutsche Bank raises ITV price target to 90 (80) pence - 'hold'

----------

Deutsche Bank raises Kainos target to 1,235 (1,050) pence - 'hold'

----------

Barclays reinitiates Softcat with 'overweight' - price target 1,800 pence

----------

Barclays cuts Dowlais price target to 105 (120) pence - 'overweight'

----------

RBC cuts Dowlais price target to 120 (150) pence - 'outperform'

----------

Barclays raises Babcock target to 560 (529) pence - 'overweight'

----------

Morgan Stanley cuts SSP Group price target to 300 (320) pence - 'overweight'

----------

Berenberg raises Cranswick price target to 5,312 (4,921) pence - 'buy'

----------

SMALL CAP, AIM AND OTHER

----------

Morgan Stanley raises Kerry Group price target to 90 (86) EUR - 'equal-weight'

----------

Berenberg raises XP Power price target to 1,950 (1,400) pence - 'buy'

----------

Barclays raises VH Global Sustainable target to 89 (88) pence - 'equal-weight'

----------

Barclays raises Greencoat Renewables target to 117 (113) pence - 'overweight'

----------

Barclays cuts Atrato Onsite target to 73 (77) pence - 'underweight'

----------

Barclays cuts Aquila European Renewables Income target to 80 (88) pence - 'equal-weight'

----------

Berenberg raises Atalaya Mining price target to 480 (410) pence - 'hold'

----------

Barclays cuts Kingspan to 'equal weight' - price target 95 EUR

----------

Jefferies raises Boku price target to 216 (204) pence - 'buy'

----------

Citigroup cuts Eutelsat to 'neutral' - price target 5.50 EUR

----------

RBC cuts Ryanair price target to 24 (25) EUR - 'outperform'

----------

Bank of America cuts Ryanair price target to 25 (28) EUR - 'buy'

----------

Goldman Sachs cuts Ryanair price target to 28 (30) EUR - 'buy'

----------

UBS cuts Ryanair price target to 24 (26.50) EUR - 'buy'

----------

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.